Saturday, 11 Oct 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    Bybit x FXStreet TradFi Report: Japan’s Historic Leadership Shift Sparks Nikkei Rally and Yen Weakness
    Bybit x FXStreet TradFi Report: Japan’s Historic Leadership Shift Sparks Nikkei Rally and Yen Weakness
    11/10/2025
    CoinEx Wraps Up TOKEN2049 Singapore 2025 Participation as Gold Sponsor, Driving Web3 Growth
    CoinEx Wraps Up TOKEN2049 Singapore 2025 Participation as Gold Sponsor, Driving Web3 Growth
    11/10/2025
    Green Cabbage Secures  Million Series B Funding to Accelerate Global Procurement Intelligence Expansion
    Green Cabbage Secures $40 Million Series B Funding to Accelerate Global Procurement Intelligence Expansion
    10/10/2025
    CHINA DRIVES STRONGEST GROWTH IN GLOBAL FACTORY PURCHASING SINCE MID-2022, WHILE NORTH AMERICAN MANUFACTURERS COOL IN SEPTEMBER: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
    CHINA DRIVES STRONGEST GROWTH IN GLOBAL FACTORY PURCHASING SINCE MID-2022, WHILE NORTH AMERICAN MANUFACTURERS COOL IN SEPTEMBER: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
    10/10/2025
    Fintech Forward 2025 Delivers with 38 Industry-Shaping Partnerships and Strategic Agreements Signed
    Fintech Forward 2025 Delivers with 38 Industry-Shaping Partnerships and Strategic Agreements Signed
    10/10/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • global
  • Business
  • june
  • announced
  • today
  •  and
  •  the
  • july
  • company
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

Immutheras Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

GlobeNews Wire
Last updated: 06/07/2025 11:23 AM
GlobeNews Wire
Share
7 Min Read
Immutheras Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions
SHARE
Immutheras Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

  • Distinguished experts Dr. Jay Skyler, Dr. Desmond Schatz, and Dr. Lawrence Steinman have joined Immuthera’s Scientific Advisory Board.
  • Immuthera will continue expanding its Scientific Advisory Board over the coming months to build a truly world-class team.
  • In collaboration with PolTREG and leading U.S. academic centers, Immuthera will be developing a pipeline of cutting-edge, clinically validated Treg cell therapies for autoimmune and neuroinflammatory diseases.

4 JULY 2025 – Immuthera, a pioneer in cell therapies for autoimmune diseases, and parent company, PolTREG (Warsaw Stock Exchange: PTG), are proud to highlight the exceptional caliber of the first three members of its Scientific Advisory Board (SAB)—a team whose collective expertise and groundbreaking achievements are shaping the future of diabetes and immunotherapy research. The support and guidance from these globally renowned scientists underscore Immuthera’s commitment to delivering innovative, safe, and effective therapies for patients worldwide.

“The collective wisdom and leadership of Drs. Skyler, Schatz, and Steinman provide Immuthera and PolTREG with an unparalleled strategic advantage. Their guidance ensures that our research and clinical programs are aligned with the highest standards of scientific rigor and patient care. Immuthera plans on expanding our SAB over the next several months to build a truly world-class team that will guide our activities in the US and beyond. With their support, Immuthera is uniquely positioned to accelerate the development of transformative therapies for type 1 diabetes and other autoimmune diseases” – said Prof. Piotr Trzonkowski, CEO of Immuthera and PolTREG.

Immuthera will be working closely with PolTREG, and US academic centers, to develop a pipeline of cutting edge and clinically validated Treg cell therapies for the treatment of autoimmune and neuroinflammatory diseases.

“Regulatory T cells (Treg cells) play a crucial role in maintaining immune homeostasis. As such, Immuthera’s and PolTREG’s delivery of Tregs offers hope for curing or controlling autoimmune diseases, including type 1 diabetes” – said Dr. Desmond Schatz.

“I am excited to provide advice as Immuthera and PolTREG test their exciting technology in the clinic” – add Dr. Lawrence Steinman.

A Scientific Advisory Board of Visionaries: Unrivaled Leadership in Diabetes and Immunology

Dr. Jay Skyler: Architect of Modern Diabetes Care

Dr. Jay Skyler stands as one of the most influential figures in type 1 diabetes research. His visionary work has transformed patient care and set new standards for clinical excellence:

  • Pioneering Intensive Insulin Therapy: Dr. Skyler’s development of patient self-monitoring and intensive insulin protocols revolutionized diabetes management, empowering millions to achieve better glycemic control.
  • Leadership in Landmark Clinical Trials: As Chairman of the NIH-sponsored Diabetes Prevention Trial – Type 1 (DPT-1) and Type 1 Diabetes TrialNet, Dr. Skyler has overseen global efforts to prevent and delay the onset of type 1 diabetes.
  • Trailblazer in Immune Intervention: He led the first NIH-funded studies using cyclosporine and monoclonal antibodies to preserve beta-cell function, paving the way for modern immune therapies.
  • Editorial and Organizational Leadership: Founding Editor-in-Chief of Diabetes Care and past President of the American Diabetes Association, Dr. Skyler’s influence extends from laboratory to clinic, and from policy to patient advocacy.
  • Recognition: His accolades include the Banting Medal for Service, the Distinction in Endocrinology Award, and the Mary Tyler Moore/S. Robert Levine Award from JDRF.

Dr. Desmond Schatz: Champion of Prevention, Genetics, and Pediatric Care

Dr. Desmond Schatz’s four-decade career has been dedicated to unraveling the mysteries of type 1 diabetes, particularly in children and adolescents:

  • Pioneering Research: Dr. Schatz has led major NIH and JDRF-funded studies on the prediction, genetics, and immunopathogenesis of type 1 diabetes, including the TEDDY program for newborn genetic screening and the Human Islet Research Network (HIRN).
  • Clinical Trial Leadership: As Principal Investigator for the University of Florida’s TrialNet Clinical Center and a founding member of DPT-1, Dr. Schatz has driven international efforts to prevent and manage type 1 diabetes.
  • Mentorship and Advocacy: A prolific author with over 400 publications, Dr. Schatz is recognized for nurturing the next generation of diabetes researchers and clinicians.
  • Honors: His distinguished service has been recognized with the Banting Medal, ISPAD Prize for Achievement, the George Eisenbarth Award, and the University of Florida College of Medicine Lifetime Achievement Award.

Dr. Lawrence Steinman: Innovator in Neuroimmunology and Autoimmune Therapies

Dr. Lawrence Steinman’s research has redefined the landscape of neuroimmunology and autoimmune disease treatment:

  • Breakthrough Therapy Development: His work at Stanford University led to the creation of Natalizumab (Tysabri), the first approved monoclonal antibody for multiple sclerosis (MS), now a standard of care worldwide.
  • Groundbreaking Discoveries: Dr. Steinman’s research unveiled the molecular link between Epstein-Barr virus and MS, earning him the 2023 Pioneer in Medicine Award.
  • Expanding the Frontiers: His expertise in antigen-specific therapies and DNA vaccines spans MS, ALS, neuromyelitis optica, and type 1 diabetes.
  • Recognition: Dr. Steinman is a recipient of the John Dystel Prize, the Charcot Prize for Lifetime Achievement, and is an elected member of both the US National Academy of Sciences and the National Academy of Medicine.

About Immuthera:

Immuthera is pioneering novel cell-based therapies for clinical development in the United States and Canada. Immuthera will be clinically developing assets initially developed by PolTREG under the US FDA regulatory framework. Immuthera will have full access to PolTREG’s Research and Development capabilities and asset pipeline along with the ability to explore novel modalities developed by US Institutions. Immuthera is currently seeking investment to pursue the manufacture and clinical development of these assets in the United States.

About PolTREG:

PolTREG is a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs). Its lead product, PTG-007, autologous Treg treatment for early-onset Type-1 Diabetes (T1D) is ready for Phase 2/3 clinical testing, for which the company is seeking a partnership. PolTREG has established a robust platform encompassing a wide range of cell therapy approaches, including polyclonal TREG, CAR-TREG, allogeneic TREG, antigen-specific TREG, and TCR-TREG therapies.

Akkodis and Deutsche Aircraft sign strategic agreement for the next generation of future-ready regional aircraft
Groq and HUMAIN Launch OpenAI’s New Open Models Day Zero
AEG and Tractor Beverage Company Take Center Stage With First-of-Its-Kind Partnership Bringing Certified Organic Craft Haymaker Tonics to Live Music Venues Nationwide
Carey International Appoints New Chief Executive Officer
Mastercard and Infosys Collaborate to Scale Cross-border Payments
TAGGED: andadvisoryautoimmuneboardcalibercellcompanydiabetesdiseasesdrivingexceptionalexchangeexpertisefirsthighlightimmunotherapyimmutheraimmutherasjulynewsnext-generationnextgenerationparentpioneerPLPLTRG00038poltregproudptgscientificsolutionsstocktherapieswarsawWarsaw:PTGworld-leadingworldleading
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

KOLKATAWOOD 2025: Powering Growth for Eastern India’s Wood, Furniture & Mattress Sector
Travel

KOLKATAWOOD 2025: Powering Growth for Eastern India’s Wood, Furniture & Mattress Sector

22/08/2025
FAIR PLAY MENARINI INTERNATIONAL AWARD: THE 29TH EDITION OFFICIALLY BEGINS
Entertainment

FAIR PLAY MENARINI INTERNATIONAL AWARD: THE 29TH EDITION OFFICIALLY BEGINS

05/07/2025
Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital
Health

Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital

30/09/2025
2025 Cross-Strait (Kunshan) Mid-Autumn Lantern Festival Opens
Travel

2025 Cross-Strait (Kunshan) Mid-Autumn Lantern Festival Opens

30/09/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?